French biotech company Gnosis by Lesaffre has highlighted recent research that substantiates the significant potential of S-adenosylmethionine (SAMe) for mood regulation and well-being support.
Metabolomic research suggests that the compound S-adenosyl-L-methionine (SAMe) may play a more critical role in infant development than previously thought while offering encouraging support for supplemental use in new mothers.
Metabolomic research suggests that the compound S-adenosyl-L-methionine (SAMe) may play a more critical role in infant development than previously thought while offering encouraging support for supplemental use in new mothers.
Globally, and particularly in the U.S., brain health is the most dynamic segment of food supplements, with Nutrition Business Journal (NBJ) projecting 8.7% sales growth for brain health in 2023 in the U.S., which Euromonitor International noted accounts for 42% of global cognition-oriented supplement sales.
According to Euromonitor’s 2020 Health and Nutrition Survey, unlike other health concerns, cognitive health is a focus across generations, with particular intrigue among consumers under the age of 45, who are reporting slightly higher interest rates than older consumers
.
Emphasis on improving and maintaining brain health was on the rise before the COVID-19 pandemic, but it has since seen even more significant growth as consumers are facing a growing need to manage their mental health. To this end, supplements in the brain health category may be geared toward helping improve mood, sleep, relaxation, creativity, focus and other brain functions.